The Skeptical Oncologist

The Health Care Blog
By BISHAL GYAWALI, MD Why conduct post approval studies at all? Atezolizumab previously received accelerated approval in second-line metastatic or advanced urothelial cancer based on response rates from a single arm trial. The results of post approval Read More...

Read the complete post at http://thehealthcareblog.com/blog/2018/02/07/the-optimistic-oncologist/


Posted Feb 07 2018, 09:09 AM by THCB
Filed under: